Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation.

Signal transduction and targeted therapy - 2 Sept 2024

Jin Ying, Huang Run-Jie, Guan Wen-Long, Wang Zhi-Qiang, Mai Zong-Jiong, Li Yu-Hong, Xiao Jian, Zhang Xing, Zhao Qi, Chen Shi-Fu, Liu Ming, Shi Yan-Xia, Wang Feng, Xu Rui-Hua

Abstract excerpt

Patients carrying mutations in polymerase epsilon/polymerase delta have shown positive responses to immune checkpoint inhibitors. Yet, prospective trials exploring the efficacy in those with polymerase epsilon/polymerase delta mutations are still lacking. A phase II clinical trial was initiated to evaluate the efficacy of toripalimab, a humanized IgG4K monoclonal antibody to human PD-1, in patients with advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to DNA Polymerase II

Share to DNA Polymerase III

Share to Mutation

Share to Neoplasms

Share to Poly-ADP-Ribose Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 39218995
DOI: 10.1038/s41392-024-01939-5
PMCID: PMC11366758

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation.PMID 39218995Read ↗

Integrating POLE/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer.Semantic proximity Read ↗

Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation.Semantic proximity Read ↗

Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.Semantic proximity Read ↗

Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitorSemantic proximity Read ↗

POLE/POLD1 mutation and tumor immunotherapy.Semantic proximity Read ↗

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapySemantic proximity Read ↗

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.Semantic proximity Read ↗

Comprehensive characterization of DNA polymerases driver variants using large genomic datasetSemantic proximity Read ↗

Four-Year Disease-Free Remission in a Patient With POLE Mutation-Associated Colorectal Cancer Treated Using Anti-PD-1 Therapy.Semantic proximity Read ↗

Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.Semantic proximity Read ↗

Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to favorable survival of tumors with POLE mutations outside the exonuclease domainSemantic proximity Read ↗

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.